Your session is about to expire
← Back to Search
Antimicrobial Photodynamic Therapy
Photodynamic Therapy for the Treatment of Chronic Rhinosinusitis
N/A
Waitlist Available
Led By Martin Desrosiers, MD
Research Sponsored by Ondine Biomedical Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group
Summary
The purpose of this study is to determine whether the use of light and a topically applied photosensitizer can relieve symptoms and clinically improve patients with chronic rhinosinusitis.
Eligible Conditions
- Sinusitis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
SNOT-22
Secondary study objectives
Microbiome evaluation
Other study objectives
CT Scoring
Endoscopic Evaluation Scoring
Nasal and sinus symptom score
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Active Control
Group I: Single photodisinfection treatmentActive Control1 Intervention
The single-treatment group will receive a single photodisinfection treatment of all involved paranasal sinuses with multiple follow-up visits.
Group II: Saline irrigationActive Control1 Intervention
Saline irrigation via syringe will be administered using a sinus irrigation catheter under endoscopic control.
Group III: Double photodisinfection treatmentActive Control1 Intervention
Patients in the double treatment arm will receive a second photodisinfection treatment 4 weeks following the first treatment with regular follow-up visits
Find a Location
Who is running the clinical trial?
Ondine Biomedical Inc.Lead Sponsor
6 Previous Clinical Trials
5,203 Total Patients Enrolled
Martin Desrosiers, MDPrincipal InvestigatorUniversité de Montréal